Clinical Trial Results: Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

View source ↗

Summary

Early add-on combination of GLP-1 receptor agonist and SGLT2 inhibitor studied in adults with cardiovascular-kidney-metabolic syndrome and related risk factors;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease Risk Factor
• Cardiovascular-kidney-metabolic Syndrome
• Kidney Disease
• Obesity Overweight
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Chung Shan Medical University | Conditions: Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor | Status: COMPLETED | Results posted: 2026-06-22